Since the U.S. Food & Drug Administration's (FDA) announcement on November 19, 2010, there's a drug on the market called, "Xgeva" (denosumab), which is prescribed for the treatment of skeletal-related events (SREs) in patients with cancer that has metastasized and damaged bone tissue. Skeletal-related events include bone fractures caused by cancer and bone pain that requires radiation. Xgeva is not approved for patients with multiple myeloma or other cancers of the blood.
Let me know just how much more information you would like to have about this drug ;-)
No comments:
Post a Comment